GLPG Galapagos NV Stock Quote

GLPG [NASD]

Index	-	P/E	-	EPS (ttm)	-1.69	Insider Own	-	Shs Outstand	65.41M	Perf Week	11.31%
Market Cap	7.28B	Forward P/E	-	EPS next Y	-6.97	Insider Trans	-	Shs Float	41.96M	Perf Month	13.67%
Income	-	PEG	-	EPS next Q	-1.46	Inst Own	11.77%	Short Float	1.59%	Perf Quarter	-9.99%
Sales	-	P/S	-	EPS this Y	-318.10%	Inst Trans	-	Short Ratio	2.63	Perf Half Y	-42.51%
Book/sh	25.49	P/B	4.37	EPS next Y	-15.80%	ROA	-	Target Price	110.83	Perf Year	-51.88%
Cash/sh	-	P/C	-	EPS next 5Y	0.71%	ROE	-	52W Range	93.01 - 274.03	Perf YTD	12.47%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-59.38%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	19.69%	ATR	3.64
Employees	1407	Current Ratio	-	Sales Q/Q	-77.60%	Oper. Margin	-	RSI (14)	59.79	Volatility	2.42% 2.23%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.85	Prev Close	111.32
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	252.87K	Price	111.32
Recom	2.90	SMA20	8.37%	SMA50	-0.33%	SMA200	-30.29%	Volume	0	Change	0.00%

Jan-19-21

Upgrade

Morgan Stanley

Equal-Weight → Overweight

$159 → $129

Nov-19-20

Initiated

Maxim Group

Buy

$170

Oct-21-20

Downgrade

Goldman

Neutral → Sell

Aug-25-20

Downgrade

Jefferies

Buy → Hold

Aug-24-20

Downgrade

H.C. Wainwright

Buy → Neutral

$270 → $123

Aug-19-20

Upgrade

Citigroup

Neutral → Buy

Aug-19-20

Downgrade

Barclays

Overweight → Equal Weight

Jul-10-20

Downgrade

Stifel

Buy → Hold

$298 → $193

Mar-30-20

Upgrade

Jefferies

Hold → Buy

$232

Mar-18-20

Upgrade

RBC Capital Mkts

Underperform → Sector Perform

$175 → $157

Feb-25-20

Downgrade

Cantor Fitzgerald

Overweight → Neutral

Feb-24-20

Downgrade

BofA/Merrill

Neutral → Underperform

Feb-20-20

Downgrade

RBC Capital Mkts

Sector Perform → Underperform

$175

Jan-06-20

Downgrade

JP Morgan

Overweight → Neutral

Dec-18-19

Downgrade

Citigroup

Buy → Neutral

Dec-17-19

Downgrade

Morgan Stanley

Overweight → Equal-Weight

Dec-13-19

Downgrade

Credit Suisse

Outperform → Neutral

$174 → $169

Dec-02-19

Initiated

BofA/Merrill

Neutral

Sep-09-19

Resumed

Morgan Stanley

Overweight

Jul-31-19

Upgrade

UBS

Neutral → Buy

Jan-21-21 02:08AM	NICE recommends Jyseleca® (filgotinib) on NHS in landmark decision for rheumatoid arthritis GlobeNewswire
Jan-12-21 11:54AM	Prime Minister announces new Commissioner of Nunavut CNW Group
Jan-11-21 04:01PM	Gilead holds 25.54% of Galapagos shares GlobeNewswire
Jan-06-21 09:30AM	Galapagos to present at 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-05-21 12:15PM	Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Galapagos NV (GLPG) Investigation ACCESSWIRE
Jan-04-21 04:05PM	Selvita completes acquisition of Fidelta from Galapagos PR Newswire
04:01PM	Selvita completes acquisition of Fidelta from Galapagos GlobeNewswire
Dec-29-20 11:50PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG ACCESSWIRE
Dec-28-20 07:00AM	Is Gilead Stock A Buy As The Company Expands Through Buyouts? Investor's Business Daily
Dec-26-20 03:24PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG Newsfile
Dec-23-20 09:20PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG ACCESSWIRE
12:00PM	Galapagos CEO makes donation of 10 million in the form of personal shares to African Parks GlobeNewswire
Dec-18-20 11:00AM	Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Galapagos NV (GLPG) Investigation ACCESSWIRE
Dec-17-20 09:35AM	Company News for Dec 17, 2020 Zacks
Dec-16-20 09:59PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG Newsfile -18.78%
04:33PM	Galapagos Stock Crumbles After Its Gilead Arthritis Deal Falls Apart Investor's Business Daily
01:42PM	Gilead (GILD) to Not Seek FDA Approval of RA Drug, Amends Deal Zacks
01:37PM	Biotech Stock Roundup: ALXN Up on Acquisition News, PFE-BNTX Get EUA for Vaccine & More Zacks
07:15AM	The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal Benzinga
Dec-15-20 04:15PM	Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib) Business Wire
04:15PM	Gilead and Galapagos announce New Commercialization and Development Agreement for Jyseleca® (filgotinib) GlobeNewswire
Dec-12-20 06:50PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG GlobeNewswire
07:20AM	3 Stocks That Are Giving Their Investors Coal in Their Stockings Motley Fool
Dec-11-20 12:44PM	Is GLPG A Good Stock To Buy Now? Insider Monkey
Dec-10-20 05:17PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG PR Newswire
06:56AM	Investors: How Would You Grade Gilead Sciences' CEO? Motley Fool
Dec-04-20 04:01PM	Galapagos increases share capital through subscription right exercises GlobeNewswire
Dec-01-20 04:01PM	Galapagos announces first dosing in MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease GlobeNewswire
08:08AM	The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit Benzinga
Nov-30-20 04:01PM	Galapagos reports positive topline results with GLPG1205 in IPF patients in PINTA Proof-of-Concept trial GlobeNewswire
Nov-28-20 06:45AM	Gilead's New CEO Is Going All-In on Acquisitions Motley Fool
Nov-23-20 04:15PM	Selvita to acquire Fidelta from Galapagos PR Newswire
Nov-09-20 04:01PM	First patient dosed with GLPG3667 in psoriasis patient Phase 1b trial GlobeNewswire
Nov-05-20 04:15PM	OncoArendi and Galapagos enter into exclusive collaboration on chitinase inhibitors in fibrosis GlobeNewswire
04:01PM	Galapagos reports Q3 2020 results GlobeNewswire
Nov-02-20 04:01PM	European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Ulcerative Colitis Business Wire
Oct-28-20 06:06PM	Gilead Sciences Benefits From Its Initial Quarter of Remdesivir Sales Barrons.com -5.80%
Oct-27-20 11:21AM	Galapagos R&D Roundtable showcases Toledo program GlobeNewswire
Oct-23-20 02:05PM	7 Unhealthy Biotech Stocks To Sell Before They Sicken Your Portfolio InvestorPlace
Oct-22-20 04:22PM	Gileads Sales Will Slip Even With Remdesivir Barrons.com
Oct-16-20 07:15AM	The Daily Biotech Pulse: Amarin Vascepa Data, Galapagos Osteoarthritis Drug Update, 4 IPOs Benzinga -6.98%
Oct-15-20 04:19PM	Galapagos and Servier report topline results for ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients GlobeNewswire
Oct-13-20 03:10PM	Gilead & Galapagos Announce Positive Data on UC Candidate Zacks
Oct-12-20 09:15AM	PHASE 2B/3 TRIAL SHOWS EFFICACY OF FILGOTINIB FOR THE INDUCTION AND MAINTENANCE OF REMISSION IN MODERATELY AND SEVERELY ACTIVE ULCERATIVE COLITIS GlobeNewswire
09:15AM	Phase 2b/3 Trial Shows Efficacy of Filgotinib for the Induction and Maintenance of Remission in Moderately and Severely Active Ulcerative Colitis Business Wire
Oct-01-20 01:54PM	Galapagos Begins Dosing With GLPG3970 in Psoriasis Study Zacks
Sep-29-20 04:01PM	Galapagos announces first dosing with Toledo compound GLPG3970 in psoriasis trial GlobeNewswire
Sep-28-20 03:01PM	Gilead & Galapagos' RA Drug Receives Approval in Europe Zacks
09:44AM	Galapagos Gets First Commercial Drug With Jyseleca Approval Zacks
Sep-27-20 05:52AM	Vertex or Galapagos: Which Biotech Stock Does The Street Favor? SmarterAnalyst
Sep-25-20 01:00PM	EUROPEAN COMMISSION GRANTS MARKETING AUTHORIZATION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ACTIVE RHEUMATHOID ARTHRITIS GlobeNewswire +5.07%
01:00PM	European Commission Grants Marketing Authorization for Jyseleca® (Filgotinib) for the Treatment of Adults With Moderate to Severe Active Rheumatoid Arthritis Business Wire
07:48AM	New Strong Sell Stocks for September 25th Zacks
02:14AM	Jyseleca® (filgotinib) approved in Japan for rheumatoid arthritis GlobeNewswire
02:14AM	Correction: Jyseleca® (filgotinib) approved in Japan for rheumatoid arthritis GlobeNewswire
Sep-18-20 04:01PM	Galapagos increases share capital through subscription right exercises GlobeNewswire
Sep-14-20 10:28AM	Gilead Just Made a Big Bet on Immunomedics Cancer Treatment. Was the Price too High? Barrons.com
09:28AM	Galapagos (GLPG) Surges: Stock Moves 8.8% Higher Zacks
05:45AM	Galapagos Pops 9% On Positive Result Of Novesa Trial SmarterAnalyst
Sep-13-20 06:17PM	Gilead's $21 Billion Deal Splurge May End in Regret Bloomberg
Sep-11-20 08:05AM	The Daily Biotech Pulse: Positive Readout From Galapagos, Intersect ENT Strikes Distribution Deal, Sol Gel's Regulatory Filing Accepted For Review Benzinga +8.78%
Sep-10-20 10:30PM	Primary endpoint achieved with ziritaxestat in NOVESA trial in systemic sclerosis patients GlobeNewswire
Sep-01-20 11:15PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG ACCESSWIRE
Aug-28-20 07:45AM	Remdesivir Data Leaves Gilead Stock Well-Positioned to Rally InvestorPlace
06:10AM	Why I Gave Up on Gilead Motley Fool
Aug-26-20 01:30AM	Galapagos to present new insights in IPF and related clinical developments at the European Respiratory Society Congress GlobeNewswire
Aug-25-20 10:45PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG GlobeNewswire
Aug-21-20 01:54AM	StockBeat: Galapagos' Halo Slips Investing.com
Aug-20-20 05:28PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG GlobeNewswire
11:45AM	Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Galapagos NV (GLPG) Investigation ACCESSWIRE
Aug-19-20 08:01PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG PR Newswire -25.03%
12:18PM	Why Galapagos Stock Is Crashing Today Motley Fool
12:00PM	Two Surprising FDA Rejections Raise Alarms for Biotech Investors Bloomberg
10:42AM	Potential Gilead Blockbusters Were Rejected By the FDA. Why Thats the Near-Worst-Case Scenario for the Stock. Barrons.com
03:46AM	Gilead arthritis drug won't be approved by FDA in current form, partner Galapagos says MarketWatch
02:48AM	Gilead Sinks After-Hours As FDA Rejects Rheumatoid Arthritis Application SmarterAnalyst
12:29AM	Gilead's Rheumatoid Arthritis Drug Application Is A No-Go In Present Form: FDA Benzinga
Aug-18-20 07:25PM	Galapagos announces that Gilead received a complete response letter for filgotinib for the treatment of moderately to severely active rheumatoid arthritis GlobeNewswire
Aug-12-20 04:01PM	Scipher Medicine and Galapagos sign collaboration in inflammatory bowel disease GlobeNewswire
Aug-06-20 04:01PM	Galapagos reports solid H1 2020 progress GlobeNewswire
Jul-24-20 08:14AM	GILEAD AND GALAPAGOS ANNOUNCE POSITIVE EUROPEAN CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS GlobeNewswire
08:10AM	Gilead and Galapagos Announce Positive European CHMP Opinion for Jyseleca® (Filgotinib) for the Treatment of Adults With Moderate to Severe Rheumatoid Arthritis Business Wire
Jul-07-20 06:48PM	5 Greenblatt Magic Formula Biotech Stocks to Weather the Summer Coronavirus Storm GuruFocus.com
Jul-02-20 10:38AM	Better Buy: Vertex Pharmaceuticals vs. Galapagos Motley Fool
Jun-26-20 12:31PM	Hedge Funds Are Warming Up To Galapagos NV (GLPG) Insider Monkey
Jun-07-20 11:15AM	AstraZeneca Ponders a Huge $240 Billion Gilead Gamble Bloomberg
Jun-05-20 04:01PM	New Analyses of Phase 2 EQUATOR Clinical Program Support Durable Efficacy of Filgotinib in Psoriatic Arthritis Business Wire
Jun-04-20 10:03AM	Stocks in Europe slip ahead of ECB decision MarketWatch
03:19AM	Galapagos shares rise on Phase 3 studies of arthritis drug it's making with Gilead MarketWatch
01:29AM	Filgotinib Demonstrates Durable Efficacy and Consistent Safety Profile at 52 Weeks in FINCH 1 and 3 Studies in Rheumatoid Arthritis Business Wire
May-21-20 11:20AM	Galapagos and Gilead Sciences Post Successful Yet Disappointing Filgotinib Results Motley Fool -7.76%
08:01AM	The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive Benzinga
05:17AM	Gilead, Galapagos Announce Positive Data on Inflammatory Drug Zacks
02:37AM	Gilead and Galapagos Score Positive Topline Results For Ulcerative Colitis Trial SmarterAnalyst
May-20-20 04:03PM	Gilead and Galapagos Announce Positive Topline Results of Phase 2b/3 Trial of Filgotinib in Moderately to Severely Active Ulcerative Colitis Business Wire
May-11-20 06:52AM	H.C. Wainwright Sticks to Their Buy Rating for Galapagos NV Investing.com +6.51%
May-09-20 10:00PM	Galapagos NV (GLPG) Q1 2020 Earnings Call Transcript Motley Fool
Apr-25-20 11:56AM	7 stock picks for a volatile market from a manager who finds innovation all over the place MarketWatch
Apr-24-20 11:41AM	7 Beautiful Biotech Stocks to Buy Here InvestorPlace
Apr-22-20 09:07AM	Why Galapagos (GLPG) Might Surprise This Earnings Season Zacks

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjogren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.A r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience